Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Zovirax on TV for the first time in six years

Cold sore treatment Zovirax will return to TV screens for the first time in six years, manufacturer GlaxoSmithKline (GSK) has announced.

The advert will run from mid-December, along with the support of a “full digital campaign”, GSK said.

It has already received a packaging refresh in November, designed to “optimise brand identity and communicate healing in as little as three days”, the manufacturer added.

Zovirax senior brand manager James Sharman said GSK is “committed” to helping educate shoppers on the benefits of the cold sore cream.

“We have conducted extensive research into how the packaging will be perceived with shoppers, which has proven extremely successful,” Mr Sharman said. “The new packaging will be more prominent on the shelf and communicate its key messages more clearly.”

Six 2g tubes of Zovirax retail at £6.60, and six 2g pump dispensers (see picture) at £7.13. To order, contact 0800 783 8881

Will you order this product?

Related Content

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD009066

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel